Givosiran (giv-ō-sa-ran) is the investigational medication in ENVISION. It is being studied to see if it can reduce the production of the ALAS-1 protein in the liver. This may reduce the production of ALA and PBG, and may have the potential to reduce porphyria symptoms.
The investigational medication is given once a month as a subcutaneous injection in your abdomen, arm, or thigh. The injection goes into the fatty tissue just under your skin. It does not go into your muscle and does not require access to a vein.